Switch theme
Sign up to access all valuation multiples
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.
2004
85
LTM Revenue $61.2M
LTM EBITDA -$25.0M
$201M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Santhera Pharma has a last 12-month revenue (LTM) of $61.2M and a last 12-month EBITDA of -$25.0M.
In the most recent fiscal year, Santhera Pharma achieved revenue of $47.0M and an EBITDA of -$33.9M.
Santhera Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Santhera Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $61.2M | XXX | $47.0M | XXX | XXX | XXX |
| Gross Profit | $36.6M | XXX | $28.3M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | -$25.0M | XXX | -$33.9M | XXX | XXX | XXX |
| EBITDA Margin | -41% | XXX | -72% | XXX | XXX | XXX |
| EBIT | -$31.4M | XXX | -$39.8M | XXX | XXX | XXX |
| EBIT Margin | -51% | XXX | -85% | XXX | XXX | XXX |
| Net Profit | -$39.5M | XXX | -$50.4M | XXX | XXX | XXX |
| Net Margin | -65% | XXX | -107% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Santhera Pharma's stock price is CHF 13 (or $16).
Santhera Pharma has current market cap of CHF 168M (or $201M), and EV of CHF 167M (or $201M).
See Santhera Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $201M | $201M | XXX | XXX | XXX | XXX | $-3.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Santhera Pharma has market cap of $201M and EV of $201M.
Santhera Pharma's trades at 4.3x EV/Revenue multiple, and -5.9x EV/EBITDA.
Equity research analysts estimate Santhera Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Santhera Pharma has a P/E ratio of -5.1x.
See valuation multiples for Santhera Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $201M | XXX | $201M | XXX | XXX | XXX |
| EV (current) | $201M | XXX | $201M | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | -8.1x | XXX | -5.9x | XXX | XXX | XXX |
| EV/EBIT | -6.4x | XXX | -5.1x | XXX | XXX | XXX |
| EV/Gross Profit | 5.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.1x | XXX | -4.0x | XXX | XXX | XXX |
| EV/FCF | -4.8x | XXX | -4.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSanthera Pharma's last 12 month revenue growth is 57%
Santhera Pharma's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.8M for the same period.
Santhera Pharma's rule of 40 is 133% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Santhera Pharma's rule of X is 101% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Santhera Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 57% | XXX | 57% | XXX | XXX | XXX |
| EBITDA Margin | -41% | XXX | -72% | XXX | XXX | XXX |
| EBITDA Growth | -98% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 133% | XXX | -16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 101% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 68% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 145% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Santhera Pharma acquired XXX companies to date.
Last acquisition by Santhera Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Santhera Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Santhera Pharma founded? | Santhera Pharma was founded in 2004. |
| Where is Santhera Pharma headquartered? | Santhera Pharma is headquartered in Switzerland. |
| How many employees does Santhera Pharma have? | As of today, Santhera Pharma has 85 employees. |
| Is Santhera Pharma publicy listed? | Yes, Santhera Pharma is a public company listed on SWX. |
| What is the stock symbol of Santhera Pharma? | Santhera Pharma trades under SANN ticker. |
| When did Santhera Pharma go public? | Santhera Pharma went public in 2006. |
| Who are competitors of Santhera Pharma? | Similar companies to Santhera Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Santhera Pharma? | Santhera Pharma's current market cap is $201M |
| What is the current revenue of Santhera Pharma? | Santhera Pharma's last 12 months revenue is $61.2M. |
| What is the current revenue growth of Santhera Pharma? | Santhera Pharma revenue growth (NTM/LTM) is 57%. |
| What is the current EV/Revenue multiple of Santhera Pharma? | Current revenue multiple of Santhera Pharma is 3.3x. |
| Is Santhera Pharma profitable? | Yes, Santhera Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Santhera Pharma? | Santhera Pharma's last 12 months EBITDA is -$25.0M. |
| What is Santhera Pharma's EBITDA margin? | Santhera Pharma's last 12 months EBITDA margin is -41%. |
| What is the current EV/EBITDA multiple of Santhera Pharma? | Current EBITDA multiple of Santhera Pharma is -8.1x. |
| What is the current FCF of Santhera Pharma? | Santhera Pharma's last 12 months FCF is -$41.6M. |
| What is Santhera Pharma's FCF margin? | Santhera Pharma's last 12 months FCF margin is -68%. |
| What is the current EV/FCF multiple of Santhera Pharma? | Current FCF multiple of Santhera Pharma is -4.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
